caspase 8 Knockout L-02 Cell Line

The choice depends on whether you are studying CASP8's role as the initiator caspase of the extrinsic apoptosis pathway in non-tumor hepatocyte context. The Knockout line is the standard tool for asking whether CASP8 is required for these processes — CASP8 is activated by death receptor (FAS, TRAIL-R, TNFR1) signaling through the DISC (death-inducing signaling complex) containing FADD; CASP8 cleaves and activates downstream executioner caspases (CASP3, CASP7) and BID (linking extrinsic to intrinsic apoptosis); critically, CASP8 also suppresses RIPK1/RIPK3-mediated necroptosis — CASP8 loss switches death receptor signaling from apoptosis to necroptosis. Overexpression is useful for studying CASP8 in heterologous expression contexts. For non-tumor hepatocyte CASP8 research, the EDITGENE CASP8 Knockout in L-02 enables study of CASP8 biology in hepatic context — hepatocytes are particularly susceptible to apoptosis-necroptosis switching in liver injury and inflammatory conditions. This product complements the parallel CASP8 Knockouts in A-549 (lung cancer) and A-375 (BRAF V600E melanoma) for systematic cross-background validation. Rescue with wild-type, catalytically-dead (C360S), or DED-deficient CASP8 enables structure-function studies. The knockout is valuable for studying apoptosis-necroptosis switching in liver injury, hepatic inflammation, and emerging RIPK1 kinase inhibitor (necrostatin-1s, GSK2982772) research.

Primary applications: • Death receptor apoptosis: FAS, TRAIL-R, or TNFR1-induced apoptosis analysis in hepatocyte context. • Apoptosis-necroptosis switching: in CASP8-null cells, death receptor signals can drive RIPK1/RIPK3-mediated necroptosis instead of apoptosis. • Liver injury research: TNF-α-induced hepatocyte death analysis given CASP8's role in inflammatory liver injury. • Cross-background validation: parallel analysis with CASP8 KOs in A-549 and A-375 (both available) for tissue context-dependent CASP8 functions. EDITGENE recommends this L-02-based model for researchers investigating hepatic apoptosis-necroptosis switching, liver injury mechanisms, and emerging necroptosis-targeting therapeutics (RIPK1 inhibitors).

Yes. CASP8 rescue experiments are well-established for apoptosis-necroptosis research: • Construct design: use a codon-modified CASP8 sequence with a small C-terminal tag (FLAG, HA). CASP8 has two N-terminal DED (death effector domain) domains and C-terminal protease domain with catalytic C360 — preserve all elements. • Catalytically-dead rescue: C360S mutation in the catalytic cysteine abolishes proteolytic activity but retains DISC binding — this rescue restores necroptosis suppression scaffolding function while preventing apoptosis. • DED-deficient rescue: DED domain mutations disrupt FADD/DISC assembly. • Functional readout: rescue should restore death receptor-induced apoptosis and necroptosis suppression. L-02-specific considerations: • L-02 is a human hepatocyte cell line widely used in Chinese hepatology research as a non-tumorigenic normal liver model — provides a complementary non-cancer hepatocyte context to HCC lines (Hep-G2, Huh-7) and hepatoblastoma (HuH-6). • Lentiviral transduction is supported with moderate efficiency. • Recent authentication studies have identified some L-02 stocks as HeLa-derived; users should authenticate their L-02 line and complement findings in other hepatocyte models.